Connexus brain-computer interface of Paradromics.
Courtesy: Paradromics
The Neurotech startup, based in Texas, Paradromics on Wednesday announced a strategic association with Saudi Arabia and said that it will establish a center of excellence of cerebral computer interface in the region.
Neom is a developing area within the northwest of Saudi Arabia that is promoted as “a center for innovation,” according to its website. The strategic investment arm of the area, the Neom Investment Fund, directed the association. The paradromic refused to reveal the amount of investment.
Paradromics is building a cerebral computer interface, or a BCI, which is a system that deciphes brain signals and translates them into commands for external technologies. The company will work with Neom to “advance in the development of BCI -based therapies” and establish the “Premier Center for BCI -based medical care” in the Middle East and North Africa, he said in a statement.
“Working together, we can accelerate the BCI innovation rate and expand access to impressive BCI -based therapies.” The CEO of Paradromics, Matt Angle, said in a statement.
Paradromics is one of the several companies that run to market BCIS, including Elon Musk's startup Neuralink. Earlier this month, Neuralink announced that he has implanted three human patients with their technology, according to a blog post. The precision neuroscience and the syncron backed by Jeff Bezos and Bill Gates have also implemented their systems in humans.
None of these companies has assured the final seal of approval of the FDA.
The Paradromics BCI, the Connexus Brain-Comuter interface, previously known as the Connexus direct data interface, is a matrix of small electrodes designed to be implemented directly in the brain tissue. The system could eventually help patients with severe paralysis to recover their ability to communicate their neuronal signals.
The company is preparing to launch its first human judgment this year and announced its official patient record in July. Paradromics technology has not yet been approved by the United States Food and Drug Administration, and still has a long way to go before commercialization. In 2023, the company received the designation of innovative devices from the FDA, whose objective is to help accelerate the process of going to the market.
Clock: Inside Paradromics, the Neuralink competitor who hopes to market brain implants before the end of the decade
